A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
MD Anderson Study Status
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Isocitrate Dehydrogenase Gene Mutation
For general questions about clinical trials: